2007
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21: 1185-1197. PMID: 17502729, PMCID: PMC3460385, DOI: 10.1097/qad.0b013e328133f285.Peer-Reviewed Original ResearchConceptsStart of HAARTCD4 cell countCell countHIV-1 RNA levelsHIV-1-infected patientsInitiation of HAARTTreatment-naive patientsDiagnosis of AIDSInjection drug useVirological responseHIV careNew AIDSCumulative incidenceParametric survival modelsClinical stageProspective studyRisk calculatorHAARTProgression rateTreatment changesPatientsDrug usePrognostic modelAIDSCells/
1998
Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy
Weiss M, Rodby R, Justice A, Hricik D, Group T. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Kidney International 1998, 54: 193-202. PMID: 9648079, DOI: 10.1046/j.1523-1755.1998.00982.x.Peer-Reviewed Original ResearchConceptsC-reactive proteinProtein-bound pentosidineDiabetic nephropathyInterleukin-6Serum creatinineFree pentosidineMonocyte/macrophage activationAdvanced glycation end product pentosidineBaseline disease activityDegree of proteinuriaSubgroup of patientsImmune activation responseProportional hazards methodsDisease activityInflammatory markersCreatinine levelsRenal functionDiabetes mellitusSerum levelsDiabetic complicationsProgression rateGroup trialsHazards methodsMacrophage activationNephropathy